Capacity development to facilitate access to fexinidazole
Objective: Support fexinidazole access for gambiense sleeping sickness patients through capacity strengthening activities at national and local levels of the health system in line with the WHO treatment guidelines.
Project start: 2020
The project, known as FEX-g-HAT, is facilitating the delivery and uptake of fexinidazole, the first all-oral treatment for sleeping sickness, into selected African endemic countries through strengthened health care capacity and coordination via: the HAT Platform, a clinical research, training and access-supporting network of over 120 institutions; through trainings in the use of new tools; and reinforced pharmacovigilance channels for introduction of the new treatment.
The FEX-g-HAT project brings together a consortium of experts: DNDi, the National Control Programmes for Human African Trypanosomiasis of the Democratic Republic of Congo and Guinea, the Research Institute for Development (IRD), and the Institute of Tropical Medicine Antwerp.
News & resources
- 22 February 2021 - HAT Platform Newsletter No. 21
- 1 April 2020 - Latest advances in control of sleeping sickness: Towards elimination, Bulletin of the Netherlands Society for Tropical Medicine and International Health
- 29 March 2020 - How clinical research can contribute to strengthening health systems in low resource countries, Tropical Medicine and Infectious Diseases
This project is part of the EDCTP2 programme, which is supported by the European Union.
Get our latest news, personal stories, research articles, and job opportunities.